CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 443 filers reported holding CRISPR THERAPEUTICS AG in Q3 2022. The put-call ratio across all filers is 0.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $538,804 | -48.7% | 9,976 | -35.3% | 0.08% | -43.3% |
| Q1 2024 | $1,050,277 | +82.5% | 15,409 | +67.6% | 0.13% | +19.6% |
| Q4 2023 | $575,482 | +521.2% | 9,193 | +350.4% | 0.11% | +314.8% |
| Q3 2023 | $92,641 | +59.6% | 2,041 | +97.4% | 0.03% | +50.0% |
| Q2 2023 | $58,049 | +20.5% | 1,034 | -2.9% | 0.02% | +12.5% |
| Q1 2023 | $48,170 | -67.1% | 1,065 | -70.4% | 0.02% | -72.9% |
| Q4 2022 | $146,259 | -90.9% | 3,598 | -85.4% | 0.06% | -91.3% |
| Q3 2022 | $1,606,000 | +1882.7% | 24,583 | +1744.2% | 0.68% | +1888.2% |
| Q2 2022 | $81,000 | -3.6% | 1,333 | 0.0% | 0.03% | +13.3% |
| Q1 2022 | $84,000 | – | 1,333 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |